Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others), by Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and

Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others), by Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Scopolamine is an alkaloid drug extracted from a plant called henbane to treat nausea and motion sickness and further to dilate the pupil in ophthalmic procedures. Scopolamine belongs to a class of drugs called anticholinergic. Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants, similar to atropine and hyoscyamine, all of which structurally mimic the natural neurotransmitter acetylcholine. It works by blocking the activity of the neurotransmitter acetylcholine, which stimulates the part of the brain that triggers nausea and vomiting, involuntary muscle movement in the lungs, and the gastrointestinal and urinary tracts. Scopolamine is also used in medicine as a sedative or hypnotic and sometimes with morphine to relieve pain. Scopolamine has also been prescribed ‘off label’ for depression, asthma, as a smoking-cessation remedy, and to relieve the nausea that accompanies chemotherapy. According to data published by National Center for Biotechnology Information, in July 2019, Scopolamine is an anticholinergic belladonna alkaloid that, through competitive inhibition of muscarinic receptors, affects parasympathetic nervous system function and acts on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Formulated as a patch, scopolamine is released continuously over three days and remains detectable in urine over a period of 108 hours. Scopolamine is contraindicated in angle-closure glaucoma and should be used with caution in patients with open-angle glaucoma due to scopolamine's ability to increase intraocular pressure.

Market Dynamics

Increasing global population suffering from stress and anxiety disorders is expected to fuel growth of the global scopolamine market. For instance, in March 2022, according to data published by the GOQii survey on the stress and mental health status of Indians, the GOQii Survey indicates that 29.31% of Indians were suffering from depression in 2021. Stress was the cause for seven out of ten patients suffering from gastrointestinal pain. According to the National Center for the Biotechnology Information around 12 percent Trusted Source of adults in the United States have Irritable bowel syndrome due to increasing stress after economic loss in covid-19 pandemic. Women are twice as likely to have Irritable bowel syndrome as men. As many as three-quarters Trusted Source of people with Irritable bowel syndrome report stress. The nervous system controls the gut and also responds to psychological stress.

Key features of the study:

• This report provides an in-depth analysis of the global scopolamine market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global scopolamine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global scopolamine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global scopolamine market

Detailed Segmentation:

• Global Scopolamine Market, By Dosage Form:
• Tablet
• Syrup
• Injection
• Patch
• Others
• Global Scopolamine Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Scopolamine Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Baxter International Inc.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• GlaxoSmithKline plc
• Novartis AG
• Perrigo Company plc.
• Caleb Pharmaceuticals, Inc.
• Myungmoon Pharma Co. LTD.
• Alchem International
• Phytex Australia
• Centroflora-Cms
• Alkaloids of Australia
• Fine Chemicals Corporation

“*” marked represents similar segmentation in other categories in the respective section.